Human ECM based platform for anti cancer drug testing CARES CAncer dRug tESti...
Human ECM based platform for anti cancer drug testing CARES CAncer dRug tESting
With 2 million cancer-related deaths and an annual cost of €100 billion, cancer constitutes a major European challenge. Cancer
treatments have considerably improved over the last decades, however, the success rate of new anti-canc...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
ICE-METs
Interstitium on a chip to explore its role in cancer metasta...
213K€
Cerrado
PID2021-129115OB-I00
HERRAMIENTAS MICROFLUIDICAS BASADAS EN HIDROGELES PARA INVES...
151K€
Cerrado
PID2021-123013OB-I00
BIOMATERIALES BIOINSPIRADOS PARA MODELAR LA INTERACCION CELU...
157K€
Cerrado
PID2021-126523OB-I00
DESARROLLO DE UN MODELO TRIDIMENSIONAL DE MELANOMA DINAMICO,...
115K€
Cerrado
ETICAN
ECM and TFEB interplay: from building multidisciplinary devi...
196K€
Cerrado
PID2019-106099RB-C41
MICROGELES BIOMIMETICOS PARA EL ESTUDIO DE LA GENERACION DE...
242K€
Cerrado
Información proyecto CARES
Duración del proyecto: 51 meses
Fecha Inicio: 2023-07-03
Fecha Fin: 2027-10-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
With 2 million cancer-related deaths and an annual cost of €100 billion, cancer constitutes a major European challenge. Cancer
treatments have considerably improved over the last decades, however, the success rate of new anti-cancer drugs in clinical trials
remains frustratingly low, limiting the opportunities for fast and accurate development of innovative targeted cancer therapies. Our
vision is to provide a bold and innovative technology that recapitulates the active part played by the human tumour
microenvironment, which has crucial roles in regulating tumour initiation, propagation, and progression, through the dynamic
crosstalk between the tumour cells and the extracellular matrix. CARES combines leading academic and non-academic experts in the
fields of matrix biology, biomaterials, microfluidics and cancer research to establish an accurate tool to assess cancer cell responses to
a variety of anti-cancer drugs. As a proof-of-concept, we will use breast cancer cells as a model system, with the perspective of
extending the system to other cancers. Our final goal is to deliver a novel and user-friendly platform that, by resembling the human
tumour microenvironment in early and advanced cancer stages, can predict, with unprecedented accuracy, the response of tumour
cells to anti-cancer therapies in vivo. This will facilitate development and testing of new drugs and narrow the gap between
translational cancer research and targeted cancer treatment, with a significant impact on society and the economy. The ambitious
scientific goal will provide the background for intense trans-sectoral and interdisciplinary training of young scientists, who will be
provided with an excellent translational research portfolio, allowing them to succeed both in academia and industry.